Options update 12-20-07: Genitope calls spike ahead of MyVax results


Genitope (NASDAQ: GTOP) plans to issue a press release after 4:00 pm EST today that will discuss the initial results of its pivotal Phase 3 clinical trial examining GTOP's MyVax (personalized immunotherapy vaccine for follicular non-Hodgkin's lymphoma). GTOP is recently down $1.24 to $3.00. GTOP call option volume of 46,827 contracts compares to put volume of 6,584 contracts according to Track Data, suggesting large price risk.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Symbol Lookup
IndexesChangePrice
DJIA+50.9012,852.13
NASDAQ+18.852,922.73
S&P 500+5.981,348.62

Last updated: February 13, 2012: 11:44 AM

Hot Stocks

General Electric

19.035+0.16(+0.85)

Alcoa

10.36+0.07(+0.68)

Apple Inc

499.60+6.18(+1.25)

Google Inc 'A'

612.285+6.375(+1.05)

Bank of America

8.265+0.195(+2.42)

Wal-Mart Stores

61.98+0.08(+0.13)

Exxon Mobil Corp

84.17+0.37(+0.44)

Ford

12.52+0.08(+0.64)

Citigroup

33.425+0.50(+1.52)

IBM

192.41-0.01(-0.01)

Yahoo

16.095-0.045(-0.28)

Starbucks

49.19+0.37(+0.76)

Microsoft

30.50+0.005(+0.02)

Home Depot

45.81+0.48(+1.06)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1329151477251 ms.